EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study

Maddalena Napolitano, Giuseppe Lauletta iD, Marianna Cimmino, Giampiero Girolomoni, Elena Pezzolo, Silvia Mariel Ferrucci, Alessandra Narcisi, Alessandro Borghi, Ester Del Duca, Marco Romanelli, Laura Bonzano, Niccolò Gori und 32 weitere

Clinical and Experimental Dermatology · 2026

DOI: 10.1093/ced/llag285 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Maddalena Napolitano und 43 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lebrikizumab, a monoclonal antibody targeting interleukin-13, has demonstrated efficacy and safety in adults with moderate-to-severe atopic dermatitis (AD), but data for older patients remain limited. We conducted a retrospective multicentre study including 90 patients aged ≥ 60 years with moderate-to-severe AD treated with lebrikizumab across 23 Italian dermatology centres. Clinical outcomes were assessed at baseline and at weeks (W) 16, 24 and 52. Mean (SD) Eczema Area and Severity Index (EASI) decreased from 23.24 (7.93) at baseline to 6.33 (6.54) at W16, 3.57 (3.74) at W24 and 2.70 (4.83) at W52 (P < 0.0001). EASI 75 (75% improvement from baseline) was achieved by 58%, 82% and 87% of patients at W16, W24 and W52, respectively. Clinical responses were similar across age groups and independent of prior biologic or Janus kinase inhibitor exposure. Adverse events occurred in 8% of patients and were mainly mild. These findings support the effectiveness and safety of lebrikizumab in older patients with AD in real-world clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, MonoclonalDermatologic AgentsHumansFemaleMaleAgedRetrospective StudiesMiddle AgedTreatment OutcomeSeverity of Illness IndexAged, 80 and overAntibodies, Monoclonal, Humanized

Substanzen

Antibodies, MonoclonallebrikizumabDermatologic AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Giuseppe Lauletta, Claudio Marasca, Luigi Gargiulo, Andrea Carugno

Zitieren

APA

Napolitano, M., Lauletta, G., Cimmino, M., Girolomoni, G., Pezzolo, E., Ferrucci, S. M., Narcisi, A., Borghi, A., Del Duca, E., Romanelli, M., Bonzano, L., Gori, N., Peris, K., Mandato, F., Errichetti, E., Esposito, M., Marasca, C., Rossi, M., Zerbinati, N., …, & Patruno, C. (2026). Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag285

Vancouver

Napolitano M, Lauletta G, Cimmino M, Girolomoni G, Pezzolo E, Ferrucci SM, et al. Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag285

BibTeX
@article{Napolitano2026,
  author = {Napolitano, Maddalena and Lauletta, Giuseppe and Cimmino, Marianna and Girolomoni, Giampiero and Pezzolo, Elena and Ferrucci, Silvia Mariel and Narcisi, Alessandra and Borghi, Alessandro and Del Duca, Ester and Romanelli, Marco and Bonzano, Laura and Gori, Niccolò and Peris, Ketty and Mandato, Filomena and Errichetti, Enzo and Esposito, Maria and Marasca, Claudio and Rossi, Mariateresa and Zerbinati, Nicola and Galdo, Giovanna and Peduto, Tiziana and Ribero, Simone and Ortoncelli, Michela and Macagno, Nicole and Mariano, Maria and Fargnoli, Maria Concetta and Di Sessa, Ilaria and Gola, Massimo and Milanesi, Nicola and Caroppo, Francesca and Scotto di Luzio, Genoveffa and Calzari, Paolo and Maurelli, Martina and Luyo Saboya, Raul Armando and Schettini, Natale and Gargiulo, Luigi and Bianco, Matteo and Dattola, Annunziata and Margiotta, Flavia Manzo and Triolo, Sara and Fratton, Zeno and Carugno, Andrea and di Vico, Francesca and Patruno, Cataldo},
  title = {Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag285}
}
Kostenlos starten →